UNITED THERAPEUTICS Corp — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
United Therapeutics reported Q3 2026 revenues of $832.5M (up 4% from $799.5M in Q3 2025), driven by Tyvaso DPI growth (+13% to $378.5M) offset by Nebulized Tyvaso decline (-12% to $125.3M). Net income fell 24% to $258.6M ($5.71 diluted EPS) from $338.7M ($7.16 diluted EPS) primarily due to R&D expenses surging 119% to $279.2M (including $125.2M in IPR&D from Thymmune Therapeutics acquisition and organ/cardiopulmonary projects). The company repurchased 980,394 shares (~2.3% of shares outstanding) under $2.0B authorization via three ASRs totaling ~$1.98B and a Rule 10b5-1 plan ($22.4M); a new $2.0B repurchase program was approved in October 2026.
Why this rating
Modest revenue growth (4%) offset by sharp R&D investment spike; net income decline material but driven by strategic spend (Thymmune acquisition, pipeline expansion). Massive share buybacks (~$2B, ~18% of $11.2B market cap) are capital-return neutral. No new product approval/discontinuation. Growth outlook stated as strong but unquantified.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.